Egene Inc (fka EGEI)

[ProfitScout]

eGene's HDA-GT12 Genetic Analyzer Demonstrates Its Revolutionary Technology for Gene Expression Market; Application Note Shows the Analyzer Provides the Automated High Throughput RNA Quality Control Analysis

IRVINE, Calif., May 31, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, announced today that its analyzer has demonstrated automated high-throughput RNA quality control analysis for the gene expression market. The application note is published in the May issue of BIOSCIENCE TECHNOLOGY.

BIOSCIENCE TECHNOLOGY is the recognized leader in delivering product news, application stories and feature stories on research techniques to those on the forefront of life science research. Each issue reaches more than 60,000 research scientists and directors, lab directors and managers, and principal investigators working in pharma, biotech, university and government labs. The article can be found at: http://www.bioprodmag.com/ShowPR~PUBCODE~090~ACCT~9000019603~ISSUE~060 5~RELTYPE~PAA~PRODCODE~00002739~PRODLETT~A.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.).

Dr. Ming S. Liu, acting CEO of eGene, noted: "Gene expression has become a mainstream technique in biology, medicine and drug development. Our HDA-GT12 platform is a revolutionary technology for RNA quality control checking. A researcher can check RNA quality for 12 samples in 10 minutes and 96 samples in less than 90 minutes.

"Our compact, automated high throughput digital HDA-GT12 genetic analyzer can play a major role in the gene expression market," he continued. "We can see increased demand in the current market, and more customers are integrating our HDA-GT12 system in their gene expression research."

The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.

About eGene Inc.

eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.

SOURCE: eGene Inc.

Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]
or
Andrew Ponzo, 312-943-1100, ext. 17
[e-mail]


Copyright Business Wire 2006